Organ-on-a-Chip Resources

Addressing the challenges of developing new modality drugs

Discover how new modality drugs are revolutionizing medicine by targeting complex diseases with cutting-edge therapies. Learn about the challenges, innovative solutions, and the role of AI and Organ-on-a-chip (OOC) technology in new modality drug development. Expert insights.

Multimodal imaging of a liver-on-a-chip model using labelled and label-free optical microscopy techniques

This recent multimodal imaging publication by Majer et al. (2024) from GSK explores the groundbreaking potential of 3D imaging of Liver-on-a-chip tissue to evaluate one of the biggest challenges in therapeutic ASOs: delivering oligonucleotides in sufficient concentration to the target tissue and cells of interest.

Validating a human dual-organ MPS for better drug (ADME) studies

In this video from Technology Networks’ Science Spotlight, Dr. Yassen Abbas, Lead scientist at CN Bio, discusses his research on ADME and how microphysiological system (MPS), also known as Organ-on-a-chip (OOC) technology can be used to evaluate the body’s effect on drugs.

The Rise of Oligonucleotide Therapeutics: Overcoming ADMET Development Challenges with Human-Centric Approaches

When developing oligonucleotide therapeutics, human-centric approaches are crucial for overcoming ADMET challenges and unlocking their full potential.

Find out through case studies how and why Organ-on-a-chip offers a path forward for the development of oligonucleotides targeting liver diseases by providing clearer insights into human-specific responses where in vivo models are less/unsuited.

How Organ-on-a-chip can reduce DILI risk in drug development

Drug-induced Liver injury is a common cause of drug withdrawal during late drug development as well as post-approval. The liver, a primary site of drug metabolism, is particularly susceptible. However, DILI can occur through several pathways, each involving different mechanisms.

This article explores why traditional in vitro and in vivo animal studies are less able to predict more complex indirect or idiosyncratic effects that are latent in onset and how preclinical workflows can be modernized to reduce risk through Organ-on-a-chip’s mechanistic insights.

Evaluating a human DILI assay kit’s ability to unlock complex mechanisms of toxicity

Here, we demonstrate how the PhysioMimix DILI assay kit: Human 24 and PhysioMimix OOC Single-organ System captures more complex mechanisms of human DILI than traditional preclinical approaches to reduce the risk of unforeseen event detection in the clinic.

Vox Pop Pharma – companies keen to find alternatives to animal testing – read their views

Earlier this week, Charles River Laboratories International, Inc. revealed its Alternative Methods Advancement Project (AMAP), which it said is a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing.

Next Generation Drug Discovery: Bridging the Gap with Organ-on-a-Chip Technology

In today’s drug development landscape, there is a critical need for more human-relevant preclinical testing models. Traditional in vitro assays and in vivo animal models often fall short in predicting human outcomes, especially as advanced drug modalities with human-specific actions become more prevalent. Organ-on-a-Chip (OOC) technology, a groundbreaking solution designed to replicate human physiology and function in vitro, offers a promising path forward.

A Gut/Liver microphysiological system for profiling human oral bioavailability

Webinar Series 7 Episode 4

Explore how the innovative Gut/Liver microphysiological system (MPS) enhances in vitro ADME profiling by linking primary human intestinal and liver cells to predict human drug bioavailability more accurately. This webinar demonstrates improved predictive capacity for complex drug behaviors, advancing drug discovery and safety assessment.

Evaluating Caco-2 cell’s gold-standard status in absorption, permeability and bioavailability Studies: Are Their Limitations Justified?

Caco-2 cells have long been heralded as the gold standard for studying intestinal absorption and permeability. However, as with any model system, Caco-2 cells have their own set of limitations. This raises important questions: Do their limitations undermine their gold-standard status? Is it time to improve estimations with more physiologically relevant approaches? What new approaches are available, and most importantly, do their benefits sufficiently outweigh the effort required to adopt a new approach?

Go/No-Go

Webinar Series 7 Episode 3

In this webinar “Go/No-Go” we demonstrate how to further de-risk development workflows with the PhysioMimix^® DILI assay. Using drugs that were identified as toxic in the clinic, we reveal some of the data-rich investigative toxicology studies that can be achieved using a human liver microphysiological system (MPS), otherwise known as organ-on-a-chip (OOC).

User Group Meeting 2024 – Recap

October 17, 2024, marked a milestone for CN Bio as we hosted our inaugural virtual conference and User Group Meeting (UGM).

Designed specifically for our customers, partners, collaborators, and those looking for practical insights into Organ-on-a-chip (OOC) adoption, the event showcased the transformative power of OOC in drug development and research.